Deciphering the role of Th17 cells in human disease

Trends in Immunology

Volumn 32, Issue 12, 2011, Pages 603-611

  Wilke, Cailin Moira ^a   Bishop, Keith ^a   Fox, David ^a   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CXCL9 CHEMOKINE; ETANERCEPT; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE DERIVED CHEMOKINE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALLERGY; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL FUNCTION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC INFLAMMATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOLOGY; ENTERITIS; GENERAL ASPECTS OF DISEASE; GRAFT REJECTION; HUMAN; INFECTION; MULTIPLE SCLEROSIS; NASOPHARYNX CARCINOMA; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TUMOR GROWTH; TUMOR IMMUNITY; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; HUMANS; HYPERSENSITIVITY; NEOPLASMS; TH17 CELLS;

EID: 81355148789     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2011.08.003     Document Type: Review

References (110)

1. Annunziato F., et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
2. Cosmi L., et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J. Exp. Med. 2008, 205:1903-1916.
3. Kleinschek M.A., et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J. Exp. Med. 2009, 206:525-534.
4. Kryczek I., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
5. Kryczek I., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J. Immunol. 2008, 181:4733-4741.
6. Kryczek I., et al. IL-17+ Regulatory T cells in the microenvironments of chronic inflammation and cancer. J. Immunol. 2011, 186:4388-4395.
7. Maggi L., et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur. J. Immunol. 2010, 40:2174-2181.
8. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 2008, 8:337-348.
9. Dubin P.J., Kolls J.K. Th17 cytokines and mucosal immunity. Immunol. Rev. 2008, 226:160-171.
10. Bettelli E., et al. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
11. Weaver C.T., Hatton R.D. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat. Rev. Immunol. 2009, 9:883-889.
12. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 10:248-256.
13. Murphy K.M., Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 2010, 11:674-680.
14. Lee Y.K., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
15. Cosmi L., et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J. Allergy Clin. Immunol. 2010, 125:222-230. e221-224.
16. Kryczek I., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 2006, 203:871-881.
17. Zou W., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.
18. Wei S., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005, 65:5020-5026.
19. Curiel T.J., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
20. Curiel T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
21. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
22. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
23. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8:467-477.
24. Kryczek I., et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
25. Kryczek I., et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 2007, 178:6730-6733.
26. Kryczek I., et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J. Immunol. 2007, 179:1423-1426.
27. Sfanos K.S., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 2008, 14:3254-3261.
28. Ye Z.J., et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J. Immunol. 2010, 185:6348-6354.
29. Chen J.G., et al. Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients. Int. J. Biol. Sci. 2011, 7:53-60.
30. Zhang Y.L., et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol. Cancer 2010, 9:4.
31. Derhovanessian E., et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 2009, 125:1372-1379.
32. Wu S., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
33. Annunziato F., Romagnani S. The transient nature of the Th17 phenotype. Eur. J. Immunol. 2010, 40:3312-3316.
34. Martin-Orozco N., et al. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 2009, 39:216-224.
35. Bending D., et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 2009, 119:565-572.
36. Nistala K., et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14751-14756.
37. Acharya M., et al. alphav Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010, 120:4445-4452.
38. Zaba L.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J. Invest. Dermatol. 2009, 129:79-88.
39. Chabaud M., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999, 42:963-970.
40. Ziolkowska M., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 2000, 164:2832-2838.
41. Hwang S.Y., Kim H.Y. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol. Cells 2005, 19:180-184.
42. Leipe J., et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010, 62:2876-2885.
43. Cascao R., et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res. Ther. 2010, 12:R196.
44. van Hamburg J.P., et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 2011, 63:73-83.
45. Hot A., Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann. Rheum Dis. 2011, 70:727-732.
46. Kirkham B.W., et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006, 54:1122-1131.
47. Wallis S.K., et al. A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. Arthritis Res. Ther. 2011, 13:R15.
48. Lundy S.K., et al. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res. Ther. 2007, 9:202.
49. Tran C.N., et al. Molecular interactions between T cells and fibroblast-like synoviocytes: role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am. J. Pathol. 2007, 171:1588-1598.
50. Sato K., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 2006, 203:2673-2682.
51. Pollinger B., et al. Th17 cells, not IL-17+ {gamma}{delta} T cells, drive arthritic bone destruction in mice and humans. J. Immunol. 2011, 186:2602-2612.
52. Zizzo G., et al. Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin. Immunol. 2011, 138:107-116.
53. Cosmi L., et al. Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011, 63:2504-2515.
54. Cooney, L.A. et al. (2011) Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J. Immunol., in press.
55. Matusevicius D., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
56. Ishizu T., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
57. Tesmer L.A., et al. Th17 cells in human disease. Immunol. Rev. 2008, 223:87-113.
58. Du C., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat. Immunol. 2009, 10:1252-1259.
59. Kebir H., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
60. McGeachy M.J., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8:1390-1397.
61. Beurel E., et al. Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J. Immunol. 2011, 186:1391-1398.
62. Kanakasabai S., et al. PPARdelta deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis. Brain Res. 2011, 1376:101-112.
63. Hao J., et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
64. Ochoa-Reparaz J., et al. Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora. Gut. Microbes 2010, 1:103-108.
65. Melton A.C., et al. Expression of alphavbeta8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 2010, 120:4436-4444.
66. Yen D., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 2006, 116:1310-1316.
67. Hue S., et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 2006, 203:2473-2483.
68. Kullberg M.C., et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 2006, 203:2485-2494.
69. Duerr R.H., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
70. Nielsen O.H., et al. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 2003, 38:180-185.
71. Rovedatti L., et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009, 58:1629-1636.
72. Bogaert S., et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol. 2010, 11:61.
73. Saruta M., et al. Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease. J. Immunol. 2007, 178:3293-3300.
74. Stevens C., et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig. Dis. Sci. 1992, 37:818-826.
75. Reinecker H.C., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 1993, 94:174-181.
76. Schwartz S., et al. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem. Biophys Res. Commun. 2005, 337:505-509.
77. Krueger G.G., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 2007, 356:580-592.
78. Mannon P.J., et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 2004, 351:2069-2079.
79. Burakoff R., et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm. Bowel Dis. 2006, 12:558-565.
80. Toichi E., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 2006, 177:4917-4926.
81. Ramgolam V.S., et al. B cells as a therapeutic target for IFN-{beta} in relapsing-remitting multiple sclerosis. J. Immunol. 2011, 186:4518-4526.
82. Ramgolam V.S., Markovic-Plese S. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. Endocr. Metab. Immune Disord. Drug Targets 2010, 10:161-167.
83. Axtell R.C., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
84. Zaba L.C., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 2007, 204:3183-3194.
85. Hueber W., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2010, 2:52ra72.
86. Genovese M.C., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010, 62:929-939.
87. Vanaudenaerde B.M., et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur. Respir. J. 2006, 27:779-787.
88. Burlingham W.J., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 2007, 117:3498-3506.
89. Faust S.M., et al. Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection. J. Immunol. 2009, 183:7297-7306.
90. Fabrega E., et al. Changes in the serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl. 2009, 15:629-633.
91. Deteix C., et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J. Immunol. 2010, 184:5344-5351.
92. Durandy A. Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur. J. Immunol. 2003, 33:2069-2073.
93. Loverre A., et al. T helper 1, 2 and 17 cell subsets in renal transplant patients with delayed graft function. Transpl. Int. 2011, 24:233-242.
94. Wang S., et al. Dynamic changes in Th1, Th17, and FoxP3(+) T cells in patients with acute cellular rejection after cardiac transplantation. Clin. Transplant. 2010, 25:E177-E186.
95. Dander E., et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation 2009, 88:1261-1272.
96. Dlubek D., et al. Interleukin-17-producing cells increase among CD4+ lymphocytes before overt manifestation of acute graft-versus-host disease. Transplant. Proc. 2010, 42:3277-3279.
97. Carvalho A., et al. Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant. 2010, 45:1645-1652.
98. Iclozan C., et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol. Blood Marrow Transplant. 2010, 16:170-178.
99. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372:1107-1119.
100. Cosmi L., et al. Th17 cells: new players in asthma pathogenesis. Allergy 2011, 66:989-998.
101. Laan M., et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 1999, 162:2347-2352.
102. Hellings P.W., et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 2003, 28:42-50.
103. Wong C.K., et al. Interleukin-17A activation on bronchial epithelium and basophils: a novel inflammatory mechanism. Eur. Respir. J. 2010, 35:883-893.
104. Milovanovic M., et al. Interleukin-17A promotes IgE production in human B cells. J. Invest. Dermatol. 2010, 130:2621-2628.
105. Geha R.S. Allergy and hypersensitivity. Nature versus nurture in allergy and hypersensitivity. Curr. Opin. Immunol. 2003, 15:603-608.
106. Vazquez-Tello A., et al. Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin. Exp. Allergy 2010, 40:1312-1322.
107. Bamberger C.M., et al. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J. Clin. Invest. 1995, 95:2435-2441.
108. Zhao Y., et al. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 2010, 151:297-307.
109. Barczyk A., et al. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 2003, 97:726-733.
110. Al-Ramli W., et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J. Allergy Clin. Immunol. 2009, 123:1185-1187.